The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

The hormone decreases a type of white blood cell that helps keep tumors in check; restricting the hormone could be a ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer ...

His book, “American Ramble,” lyrically recounted a 330-mile trek from Washington, D.C., to New York City while he was in ...

A recent report by the American Association for Cancer Research suggests adding cancer-specific warning labels to alcoholic ...

Many Americans are unaware of the connection between drinking and cancer risk, despite growing research that points to the negative health impacts of alcohol.

Even 1 drink a day can increase the risk of several cancers, including breast and colorectal cancers, according to a new ...

It’s probably the single worst thing you can do for yourself,” Dr. Jeremy London, a heart surgeon based in Savannah, said ...

Steve Langion was a firefighter, paramedic, ski patroller and a revered member of the Telluride community. He was always ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

Drawing in the organs of individual breast cancer patients and then creating precise radiation plans appears to be faster by ...